The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO)‘s stock had its “neutral” rating restated by equities research analysts at The Goldman Sachs Group in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. They currently have a $41.00 target price on the stock, down from their previous target price of $63.00. The Goldman Sachs Group’s price objective points to a potential upside of 11.78% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. HSBC restated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, CICC Research began coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Five research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $53.93.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $36.68 on Monday. The stock has a 50-day moving average price of $52.24 and a 200 day moving average price of $52.68. The stock has a market capitalization of $163.78 billion, a P/E ratio of 10.57 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $91.90. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. lifted its position in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after buying an additional 13,658,867 shares during the last quarter. Capital International Investors increased its position in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the last quarter. Boston Partners purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at $310,199,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after acquiring an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 851.6% during the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after purchasing an additional 4,302,126 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Large Ireland manufacturing investments to defend market share and expand oral GLP‑1 capacity — boosts production flexibility and long‑term revenue defense. Novo Nordisk to invest $506 million in Ireland plant expansion
• Positive Sentiment: Major facility upgrade announced in Athlone (≈€432m) to add tabletting capacity for oral GLP‑1s, underlining commitment to scaling production outside the U.S. Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
• Positive Sentiment: Share repurchase program underway (part of up to DKK 15bn plan) — supports EPS and signals capital-return priority amid near‑term headwinds. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Morgan Stanley upgraded NVO to Equal‑weight, saying the recent sell‑off better prices mid‑term risks and setting a $40 target — a modest analyst tailwind. Morgan Stanley upgrades Novo Nordisk, says risks better priced after sell-off
• Neutral Sentiment: Goldman Sachs reaffirmed a neutral rating but cut its price target, reflecting mixed views on near‑term margin/volume pressures vs. strategic moves. (Coverage note)
• Negative Sentiment: FDA ordered Novo to stop a consumer Ozempic ad for being false or misleading — raises regulatory risk, potential ad pullbacks and reputational concerns around product claims. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Investor class‑action investigation announced (Pomerantz) — could increase legal/settlement risk and add near‑term selling pressure. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Planned US list‑price cut for Wegovy (halved in 2027) — directly pressure on revenue and pricing power in the U.S. obesity market. Novo Nordisk to halve US list price of Wegovy in 2027
• Negative Sentiment: Generic/competitor threats: Aspen expects Canadian approval for a generic Ozempic formulation this year, which could erode market share outside the U.S. Aspen expects Canada nod for generic Ozempic this year
• Negative Sentiment: Competitive pressure rising — Roche is targeting double‑digit share in weight‑loss and Eli Lilly’s recent head‑to‑head clinical wins have intensified investor concern about GLP‑1 market share. Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.